SCHEMBL27226113

SCHEMBL27226113

N#Cc1nccc(NC2CNC2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.68
▸ HRH3 Q9Y5N1 3/20 0.60
▸ FLT3 P36888 7/20 0.44
▸ MALT1 Q9UDY8 1/20 0.39
▸ CYP1A2 P05177 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ ALOX15 P16050 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ IRAK4 Q9NWZ3 3/20 0.38
▸ HRH4 Q9H3N8 1/20 0.37
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ NRAS P01111 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23830882 0.88 CTSK (0.66) CTSKHRH3FLT3CYP1A2IRAK4
SCHEMBL23830884 0.88 CTSK (0.66) CTSKHRH3FLT3CYP1A2IRAK4
SCHEMBL30815053 0.85 CTSK (0.74) CTSKHRH3MALT1CYP1A2IRAK4
SCHEMBL27226580 0.85 CTSK (0.74) CTSKHRH3MALT1CYP1A2IRAK4
SCHEMBL30815456 0.82 CTSK (0.62) CTSKHRH3FLT3MALT1CYP1A2
SCHEMBL27227105 0.82 CTSK (0.62) CTSKHRH3FLT3MALT1CYP1A2
SCHEMBL31061062 0.81 CTSK (1.00) CTSKHRH3MALT1ALDH1A1PRKD1
SCHEMBL30815035 0.79 CTSK (0.58) CTSKHRH3FLT3MALT1CYP1A2
SCHEMBL27225969 0.79 CTSK (0.65) CTSKHRH3MALT1CYP1A2CYP3A4
SCHEMBL27226207 0.79 CTSK (0.58) CTSKHRH3FLT3MALT1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
WO-2025128834-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 — — US disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 CTSK 2726/4885HRH3 3939/4885FLT3 1318/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 CTSK 2726/4885HRH3 3939/4885FLT3 1318/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 CTSK 2726/4885HRH3 3939/4885FLT3 1318/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 CTSK 2726/4885HRH3 3939/4885FLT3 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback